The aim of this study was to analyze the side effects of TNF-α inhibitors reported to the Agency for Medicinal Products and Medical Devices of Croatia in the period from 1 January 2018 to 31 December 2019, and to raise awareness of the safety profile of these drugs and risk minimization measures, especially additional measures. Reports of suspected adverse reactions were analyzed in relation to the total number of suspected reports of adverse reactions in the given period, then by reporter qualification, by age and sex of the patient, suspected drug, most common concomitant drugs, severity of reaction, reported adverse reactions by MedDRA organic classification (the Medical Dictionary for Regulatory Affairs), the most commonly reported side effects, and the most serious side effects. A total of 246 applications were received, mostly for patients between the ages of 18 and 64 (74,4 %) and for female patients (60,6 %). The most common reporters were physicians (86,2 %). Most reports were received on infliximab and adalimumab, while drugs co-administered with TNF-α inhibitors most often belonged to the group of immunosuppressants and analgesics. 61 % of applications met some criterion of severity, most often "other medically important conditions". Most side effects have been received for general and on-site reactions, and the most common reaction is drug ineffectiveness. Of the serious side effects, infections were the most common. The obtained results and overall knowledge about the safety profile of TNF-α inhibitors and risk minimization measures enable additional education of healthcare professionals on easier prevention, detection and treatment of possible side effects in order to preserve the quality of life of patients.